Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancerCF Singer, YY Tan, Florian Fitzal et al.|Cancer Research|2017Cited by 2